ID110460002 

ID110460002 possesses both full agonist activity at the μ-opioid receptor (OPRM) and agonist activity at the δ-opioid receptor (OPRD). ID110460002 acts as a potent agonist for the G protein pathways of both receptors, but exhibits only very weak partial agonist activity towards the β-arrestin-2 pathway. The agonistic potency of ID110460002 at OPRM has extremely high intrinsic activity and is unaffected by reduced receptor expression levels, while its potency at OPRD depends on receptor expression levels. ID110460002 displays tissue- or organ-dependent properties, and serves as a critical compound for investigating pain mechanisms and analgesia^[1].

ID110460002 acts as a full G protein agonist in HEK-293 cells overexpressing OPRM, with high intrinsic activity that resists receptor depletion, and exhibits an E_max of 77.8% upon treatment with 10 nM β-FNA (HY-160938)^[1].
ID110460002 acts as a very weak partial agonist of the β-arrestin2 pathway in HEK-293 cells overexpressing OPRM, with an E_max of 15.3% relative to DAMGO (HY-P0210)^[1].
ID110460002 acts as a partial G protein agonist in HEK-293 cells overexpressing OPRD, and its potency decreases with reduced receptor abundance; when treated with 1000 nM β-CNA (HY-141468), its E_max reaches 64.6%^[1].
ID110460002 acts as a very weak partial agonist of the β-arrestin2 pathway in HEK-293 cells overexpressing OPRD, with an E_max of 4.7% relative to SNC80 (HY-101202)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

356.45

C₂₀H₂₅FN₄O

1172882-21-1

O=C(NC1=CC=C(F)C=C1)NCC(C2=CC=C3C(=C2)CCN3C)N(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lee JH, et al. Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists. ACS Pharmacol Transl Sci. 2021;4(3):1149-1160. Published 2021 Apr 6.  [Content Brief]